Literature DB >> 12061874

Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).

Maria Elena Y Francisco1, Herbert H Seltzman, Anne F Gilliam, René A Mitchell, Sharyl L Rider, Roger G Pertwee, Lesley A Stevenson, Brian F Thomas.   

Abstract

Analogues of the biaryl pyrazole N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716; 5) were synthesized to investigate the structure-activity relationship (SAR) of the aminopiperidine region. The structural modifications include the substitution of alkyl hydrazines, amines, and hydroxyalkylamines of varying lengths for the aminopiperidinyl moiety. Proximity and steric requirements at the aminopiperidine region were probed by the synthesis of analogues that substitute alkyl hydrazines of increasing chain length and branching. The corresponding amide analogues were compared to the hydrazides to determine the effect of the second nitrogen on receptor binding affinity. The N-cyclohexyl amide 14 represents a direct methine for nitrogen substitution for 5, reducing the potential for heteroatom interaction, while the morpholino analogue 15 adds the potential for an additional heteroatom interaction. The series of hydroxyalkyl amides of increasing chain length was synthesized to investigate the existence of additional receptor hydrogen binding sites. In displacement assays using the cannabinoid agonist [(3)H](1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl) cyclohexan-1-ol (CP 55 940; 2) or the antagonist [(3)H]5, 14 exhibited the highest CB(1) affinity. In general, increasing the length and bulk of the substituent was associated with increased receptor affinity and efficacy (as measured in a guanosine 5'-triphosphate-gamma-[(35)S] assay). However, in most instances, receptor affinity and efficacy increases were no longer observed after a certain chain length was reached. A quantitative SAR study was carried out to characterize the pharmacophoric requirements of the aminopiperidine region. This model indicates that ligands that exceed 3 A in length would have reduced potency and affinity with respect to 5 and that substituents with a positive charge density in the aminopiperidine region would be predicted to possess increased pharmacological activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061874     DOI: 10.1021/jm010498v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis.

Authors:  Elena Cichero; Giulia Menozzi; Andrea Spallarossa; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2008-08-12       Impact factor: 1.810

2.  O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.

Authors:  Bernd Jergas; Kirsten Schulte; Laura Bindila; Beat Lutz; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-23       Impact factor: 3.000

3.  Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.

Authors:  Wei Chen; Zhenhua Chen; Nina Xue; Zhibing Zheng; Song Li; Lili Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-26       Impact factor: 3.000

4.  Probing the interaction of SR141716A with the CB1 receptor.

Authors:  Joong-Youn Shim; Alexander C Bertalovitz; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-09-20       Impact factor: 5.157

5.  3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

Authors:  Jenny L Wiley; Dana E Selley; Pinglang Wang; Rudresha Kottani; Srinivas Gadthula; Anu Mahadeven
Journal:  J Pharmacol Exp Ther       Date:  2011-11-15       Impact factor: 4.030

6.  Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.

Authors:  Yanan Zhang; Anne Gilliam; Rangan Maitra; M Imad Damaj; Julianne M Tajuba; Herbert H Seltzman; Brian F Thomas
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

7.  A putative 'pre-nervous' endocannabinoid system in early echinoderm development.

Authors:  G A Buznikov; L A Nikitina; V V Bezuglov; M E Y Francisco; G Boysen; I N Obispo-Peak; R E Peterson; E R Weiss; H Schuel; B R S Temple; A L Morrow; J M Lauder
Journal:  Dev Neurosci       Date:  2009-11-12       Impact factor: 2.984

8.  Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.

Authors:  Peng Yang; Kyaw-Zeyar Myint; Qin Tong; Rentian Feng; Haiping Cao; Abdulrahman A Almehizia; Mohammed Hamed Alqarni; Lirong Wang; Patrick Bartlow; Yingdai Gao; Jürg Gertsch; Jumpei Teramachi; Noriyoshi Kurihara; Garson David Roodman; Tao Cheng; Xiang-Qun Xie
Journal:  J Med Chem       Date:  2012-10-31       Impact factor: 7.446

9.  Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

Authors:  Peng Yang; Liping Wang; Rentian Feng; Abdulrahman A Almehizia; Qin Tong; Kyaw-Zeyar Myint; Qin Ouyang; Mohammed Hamed Alqarni; Lirong Wang; Xiang-Qun Xie
Journal:  J Med Chem       Date:  2013-03-01       Impact factor: 7.446

10.  Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

Authors:  Morgan Le Naour; Eyup Akgün; Ajay Yekkirala; Mary M Lunzer; Mike D Powers; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.